Humanigen announces positive topline study results
Humanigen announced positive topline results from a preclinical study demonstrating that use of the Company’s proprietary anti-GM-CSF antibody, lenzilumab, along with CD19 targeted CART19 reduces neurotoxicity and cytokine release syndrome and enhances CART19 proliferation. August 20, 2018